View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
March 2, 2021updated 12 Jul 2022 11:22am

Saama Technologies and Oracle partner to expedite clinical trials

Saama Technologies has partnered with Oracle to offer life sciences industry artificial intelligence (AI) enabled applications to accelerate clinical trials.

Saama Technologies has partnered with Oracle to offer life sciences industry artificial intelligence (AI) enabled applications to accelerate clinical trials.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Under the partnership, Saama will integrate its smart applications with the Oracle Health Sciences Clinical One platform.

With the ability to accelerate validation of clinical trial data, Saama’s purpose-built clinical applications are technology-agnostic and enable biopharma to take the power of AI further with an ‘Intelligent Clinical Cloud’ architecture.

Saama stated that the new partnership allows pharmaceutical companies with AI-driven real-time insights to expedite their clinical trials, which is now a critical requirement due to the global pandemic.

Oracle Health Sciences Life Science Product Strategy global vice-president James Streeter said: “The current global pandemic reinforced the need for speed and accuracy in clinical development to deliver safe and effective new therapies to patients, not just for Covid-19, but across the spectrum of human disease.

“By connecting Saama’s smart applications to Clinical One Data Collection and DMW, we are able to help our life sciences customers advance their drug development timelines. Saama’s smart applications, combined with the Oracle platform, equip clinical trial teams with real-time insight to make faster decisions.”

The applications including Smart Data Query, Smart Auto Mapper, Smart Programming Analytics & Computing Environment will be available as integrated add-ons to the Oracle Clinical One platform that include Clinical One Data Collection and Data Management Workbench (DMW).

Saama stated that its AI models are trained using several clinical data points and can be easily embedded into the existing infrastructure and business workflows.

This collaboration offers scale, agility, integrated user experience, and quick outcomes from clinical applications.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena